Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Correction to: Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).
Journal: Kidney360
Published: May 07, 2026
Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status.
Journal: Kidney international reports
Published: March 25, 2026
Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses.
Journal: Diabetes, obesity & metabolism
Published: February 03, 2026
A Randomized Clinical Trial of Kidney Autologous Cell Therapy in Diabetic Kidney Disease.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: September 16, 2025
Cumulative Effects of Vicadrostat and Empagliflozin on Albuminuria in CKD.
Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
Published: May 13, 2025
Tenapanor improves long-term control of high phosphate concentrations in the blood in patients receiving maintenance dialysis: a plain language summary of the NORMALIZE study.
Journal: Current medical research and opinion
Published: July 23, 2024
Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and Type 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Redosing Triggers.
Journal: American journal of nephrology
Published: December 06, 2023
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Journal: Lancet (London, England)
Published: October 05, 2023
A phase 3b, multicenter, open-label, single-arm study of roxadustat within a US dialysis organization: The DENALI study.
Journal: Hemodialysis international. International Symposium on Home Hemodialysis
Published: January 10, 2023
Last Updated: 09/26/2026